Henry Schein, Inc. (HSIC) Shares Bought by Ashfield Capital Partners LLC
Ashfield Capital Partners LLC boosted its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 90.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 81,679 shares of the company’s stock after buying an additional 38,704 shares during the period. Ashfield Capital Partners LLC owned approximately 0.05% of Henry Schein worth $6,697,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. YorkBridge Wealth Partners LLC increased its stake in Henry Schein by 5.2% during the second quarter. YorkBridge Wealth Partners LLC now owns 570 shares of the company’s stock worth $104,000 after purchasing an additional 28 shares during the period. Sun Life Financial INC increased its stake in Henry Schein by 8,185.7% during the second quarter. Sun Life Financial INC now owns 580 shares of the company’s stock worth $106,000 after purchasing an additional 573 shares during the period. Trust Co. of Vermont increased its stake in Henry Schein by 56.7% during the third quarter. Trust Co. of Vermont now owns 1,702 shares of the company’s stock worth $140,000 after purchasing an additional 616 shares during the period. Lee Financial Co increased its stake in Henry Schein by 100.0% during the third quarter. Lee Financial Co now owns 1,756 shares of the company’s stock worth $144,000 after purchasing an additional 878 shares during the period. Finally, Benjamin F. Edwards & Company Inc. increased its stake in Henry Schein by 281.8% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,100 shares of the company’s stock worth $172,000 after purchasing an additional 1,550 shares during the period. Hedge funds and other institutional investors own 53.07% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Henry Schein, Inc. (HSIC) Shares Bought by Ashfield Capital Partners LLC” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.watchlistnews.com/henry-schein-inc-hsic-shares-bought-by-ashfield-capital-partners-llc/1707506.html.
HSIC has been the topic of a number of recent research reports. Jefferies Group LLC reiterated a “hold” rating and set a $88.50 price target on shares of Henry Schein in a research note on Friday, July 21st. BidaskClub lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Northcoast Research upgraded shares of Henry Schein from a “neutral” rating to a “buy” rating and set a $109.00 target price on the stock in a research note on Monday, August 7th. Zacks Investment Research lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Finally, Credit Suisse Group restated a “hold” rating and set a $87.50 target price on shares of Henry Schein in a research note on Tuesday, August 29th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $89.88.
Shares of Henry Schein, Inc. (NASDAQ HSIC) traded up $1.30 on Thursday, reaching $69.27. The company had a trading volume of 1,725,234 shares, compared to its average volume of 1,144,522. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86. The firm has a market capitalization of $10,490.83, a P/E ratio of 18.75, a price-to-earnings-growth ratio of 1.88 and a beta of 1.03. Henry Schein, Inc. has a 52-week low of $65.28 and a 52-week high of $93.50.
Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.03). The business had revenue of $3.16 billion during the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a net margin of 4.52% and a return on equity of 19.71%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $0.84 earnings per share. equities research analysts predict that Henry Schein, Inc. will post 3.6 EPS for the current fiscal year.
Henry Schein announced that its board has authorized a stock buyback plan on Monday, September 18th that permits the company to repurchase $400.00 million in shares. This repurchase authorization permits the company to purchase up to 6.3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
In related news, SVP Paul Rose sold 2,126 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total value of $366,756.26. Following the completion of the transaction, the senior vice president now directly owns 17,841 shares of the company’s stock, valued at $3,077,750.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.19% of the company’s stock.
Henry Schein Profile
Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.
Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.